EAS Consulting Group’s John Bailey continues to chronicle regulatory developments under the Modernization of Cosmetic Regulations Act. In this installment, he outlines industry stakeholders’ questions and concerns related to 2023 announcements from the US FDA and provisions of the law that became effective (if not yet enforced) at year-end.

The compliance clock is ticking! A breakdown of key requirements under new cosmetics regulations and related developments in recent weeks.

If the FDA reviews companies’ product information submitted under the Modernization of Cosmetics Regulations Act of 2022, which is due by 29 December 2023, and denies product listings deemed noncompliant, that could place products containing unapproved color additives and certain drug active ingredients, for example, in violation of the law.

EAS Consulting Group’s John Bailey is checking in with HBW Insight periodically in 2023 to offer his views on developments under the US Modernization of Cosmetic Regulations Act of 2022. Here he provides his experience with, and takeaways from, the US FDA’s 1 June virtual “listening session” on good manufacturing practices for cosmetic products.

John Bailey, independent advisor for colors and cosmetics at EAS Consulting Group, is checking in with HBW Insight periodically in 2023 to offer his views on developments under the US Modernization of Cosmetic Regulations Act of 2022. Here he discusses the urgent need for FDA guidance as deadlines creep closer for registration, product listing, safety substantiation, and adverse event reporting.